Drug makers now pay for trial costs—but who really benefits?
S. 4440 — Clinical Trial Modernization Act · Filed by Tim Scott (R-SC) · 1 cosponsor · Introduced Apr 29, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill removes federal barriers to paying clinical trial participants for their expenses and providing them digital health tools, and allows drug/device makers to cover patients' insurance cost-sharing in trials. It authorizes grants for community outreach to recruit underrepresented groups into clinical trials, and excludes up to $2,000 per year of trial participation payments from participants' taxable income.
Why we flagged it
The bill's core mechanism is removing legal barriers to participant compensation and cost-sharing assistance in clinical trials, paired with grants for community recruitment of underrepresented populations. It is fundamentally an access and equity measure, not a deregulation or industry carve-out.
What the text implies
- Manufacturers gain significant discretion to design cost-sharing assistance programs; the bill's safeguards (enrollment caps, informed consent, IRB oversight) are necessary but depend on enforcement and may not prevent subtle steering of trial design toward profitable indications.
- The $2,000 annual tax exclusion for trial participation income may create a perverse incentive for participants to enroll in multiple trials simultaneously to maximize tax-free income, potentially compromising data integrity or participant safety if not monitored.
- Removing the legal barrier to manufacturer-funded cost-sharing may shift the burden of trial accessibility from public health systems and insurers to manufacturers, concentrating control over who can afford to participate in the hands of companies with financial interest in trial outcomes.
- The bill does not establish a public registry or transparency requirement for manufacturer cost-sharing programs, leaving no systematic way to audit whether assistance is truly reaching underrepresented populations or being used to preferentially enroll profitable patient subgroups.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary people gain direct financial access to clinical trials (travel, meals, insurance cost-sharing covered), which removes a documented barrier to participation, especially for underrepresented and lower-income populations. The bill also funds community outreach and training to increase diversity in trial recruitment and investigator roles, strengthening the evidence base for treatments affecting all populations.
Who stands to gain
- pharmaceutical manufacturers
- medical device manufacturers
- clinical trial sponsors
- contract research organizations (CROs)
- community health centers (as grant recipients)
Named in the bill
National Institutes of Health (NIH), Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), Social Security Act Section 1128A (Anti-Kickback Statute), Social Security Act Section 1128B (Civil Monetary Penalties Law), False Claims Act (31 U.S.C. §§ 3729–3733), Internal Revenue Code Section 139J (new), Public Health Service Act Section 2709, Federal Food, Drug, and Cosmetic Act Sections 505(z) and 520(g)(9)
Where it stands
1 cosponsor: 1 Democrats.
- Apr 29, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Apr 29, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
8 lobbying clients named this bill on 8 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,715,779 in lobbying spend. A filing names 12 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 88% of bills with at least one filing.
Tim Scott, the sponsor, reported $214,300 in PAC receipts in the 2026 cycle.
- Astrazeneca Pharmaceuticals Lp — $1,680,000 on 1 filing
- American Cancer Society Cancer Action Network Inc — $1,240,000 on 1 filing
- Association for Clinical Oncology — $480,000 on 1 filing
- The Susan G. Komen Breast Cancer Foundation, Inc. Dba Susan G. Komen — $130,000 on 1 filing
- Astct — $70,000 on 1 filing
Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (9,904 characters) on May 21, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 21, 2026 · page rendered 2026-10-20.
“Drug makers now pay for trial costs—but who really benefits?” QuorumCivic. https://share.quorumcivic.app/bill/119/s4440 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.